News and Announcements
Antisense Therapeutics To Undertake Clinical Trial of ALT1102 in Duchenne Muscular Dystrophy at the Melbourne Royal Children’s Hospital
- Published June 26, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Antisense Therapeutics (ANP) has announced that the company has undertaken advanced planning for the clinical trial of ALT1102, its immunomodulatory therapy initially in development for the treatment of Multiple Sclerosis (MS). The trial is designed to assess the drug’s effects on the inflammation associated with this rare and incurable muscle wasting disease of children (Duchenne Muscular Dystrophy).
KEY TAKEAWAYS:
- Company to undertake a clinical trial of its drug ATL1102 in new clinical application, Duchenne Muscular Dystrophy
- Clinical trial is planned to be undertaken at the Royal Children’s Hospital (RCH), Melbourne
- World class international advisory board established chaired by Mr William Goolsbee ANP’s non-executive director and ex-Chairman of Sarepta Therapeutics
- Funding secured for the trial (subject to receipt of approval to commence the trial)
- Australian Ethical Investment to become largest shareholder in the Company
Mark Diamond, CEO of Antisense Therapeutics said: “Our plan to undertake a clinical trial of ATL1102 in DMD patients is facilitated by the extensive pre-clinical and clinical experience that we have established via ATL1102’s development in MS. As DMD is a rare disease with a high unmet medical need, ATL1102 is expected to benefit materially from development incentives, including orphan drug designation that are provided to support rare disease drug development”.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
